Indium-111

Indium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas). Indium In-111 is a radioisotope with a physical half-life of 2.83 days, used to label agents for diagnosis, disease progression and treatment. (NCI). It is grouped under the following drug class(es): Radiopharmaceuticals. Its therapeutic use is listed as diagnostic agents. The directory classifies it as a commercial API with a mineral/inorganic source/manufacturing origin. Other names for this substance include Indium In-111 and 111In radioisotope. Its PubChem CID is 5462099.

CAS No 15750-15-9
Molecular Formula In
Molecular Weight 110.91 g/mol
Synonyms indium-111

Frequently Asked Questions